Compounds > hunanamycin a
Page last updated: 2024-11-13

hunanamycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

hunanamycin A: antibiotic from a marine-derived Bacillus hunanensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71521235
CHEMBL ID5177659
SCHEMBL ID16389619
MeSH IDM0584718

Synonyms (3)

Synonym
hunanamycin a
SCHEMBL16389619
CHEMBL5177659

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In addition, no acute oral toxicity was observed for compound 36 in Swiss albino mice dosed up to 2 g/kg."( Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
MacMillan, JB; Reddy, DS; Shingare, RD, 2022)		1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1908189Acute toxicity in Swiss albino mouse assessed as mortality at 2 g/Kg, po administered daily for 14 days2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908183Solubility of compound in DMSO at pH 7.4 after 5 mins measured by HPLC analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908182Solubility of compound in DMSO at pH 4.5 after 5 mins measured by HPLC analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908185Stability in human plasma measured after 60 mins LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1853750Antibacterial activity against Salmonella enterica ATCC 6539 assessed as bacterial cell growth inhibition measured after 24 hrs by Bactiter-glo assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
AID1908181Solubility of compound in DMSO at pH 2.2 after 5 mins measured by HPLC analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908188Plasma protein binding in human measured at 150 uM preincubated for 30 mins followed by addition of dialysis buffer measured after 4 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908186Metabolic stability in mouse liver microsomes measured at 1 uM after 30 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908179Antibacterial activity against Salmonella enterica ATCC 6539 assessed as microbial cell viability incubated for 24 hr by quantification of ATP multimode plate reader method2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908184Solubility of compound in DMSO at pH 10.2 after 5 mins measured by HPLC analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908180Solubility of compound in DMSO at pH 1.2 after 5 mins measured by HPLC analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908187Metabolic stability in human liver microsomes measured at 1 uM after 30 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
AID1908190Acute toxicity in Swiss albino mouse assessed as lethal dose administered orally daily for 14 days2022European journal of medicinal chemistry, Jun-05, Volume: 236Antibiotic natural product hunanamycin A: Lead identification towards anti-Salmonella agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		3.5110organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		3.0540mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.1510copper group element atom;
elemental gold
elaiophylin
[no description available]		3.5110lactol;
macrodiolide;
monosaccharide derivative		antifungal agent;
autophagy inhibitor;
bacterial metabolite
azalomycin-f
azalomycin-F: a macrocyclic lactone antibiotic		3.5110
clasto-lactacystin beta-lactone
clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source		3.5110
marizomib
marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source		3.5110beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide		antineoplastic agent;
proteasome inhibitor
aspulvinone E
4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one : A member of the class of butenolides that is furan-2(5H)-one substituted by 4-hydroxyphenyl, hydroxy and 4-hydroxybenzylidene groups at positions 3, 4 and 5, respectively.. aspulvinone E : A 4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one in which the double bond adopts a Z-configuration. It is a marine metabolite isolated from the fungus Aspergillus terreus and exhibits antiviral activity.		3.51104-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one;
aspulvinone		antiviral agent;
Aspergillus metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
marine metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatocellular Carcinoma
[description not available]		02.1510
Cancer of Liver
[description not available]		02.1510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1510
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1510